Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 15/20 | 0.72 |
| ▸ | CDK9 | P50750 | 15/20 | 0.72 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | EDNRB | P24530 | 1/20 | 0.48 |
| ▸ | EDNRA | P25101 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4103869 | 0.90 | CDK9 (0.82) | CCNT1CDK9PLK1EDNRARXFP1 | |
| SCHEMBL17352241 | 0.88 | CCNT1 (0.72) | CCNT1CDK9EDNRARXFP1MAPT | |
| SCHEMBL17352245 | 0.87 | CCNT1 (0.71) | CCNT1CDK9EDNRBEDNRARXFP1 | |
| SCHEMBL17352238 | 0.87 | CCNT1 (0.71) | CCNT1CDK9EDNRBEDNRARXFP1 | |
| SCHEMBL17352240 | 0.87 | CCNT1 (0.66) | CCNT1CDK9EDNRBEDNRARXFP1 | |
| SCHEMBL17352239 | 0.87 | CCNT1 (0.70) | CCNT1CDK9EDNRARXFP1MAPT | |
| SCHEMBL17352236 | 0.86 | CCNT1 (0.59) | CCNT1CDK9EDNRAMAPTALDH1A1 | |
| SCHEMBL17352253 | 0.86 | CCNT1 (0.71) | CCNT1CDK9PLK1EDNRBEDNRA | |
| SCHEMBL15870373 | 0.86 | CCNT1 (0.69) | CCNT1CDK9EDNRARXFP1MAPT | |
| SCHEMBL17352267 | 0.84 | CCNT1 (0.76) | CCNT1CDK9PLK1EDNRARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150368209-A1 | 4-Pyrimidinylamino-benzenesulfonamide derivatives and their use for the inhibition of polo-like kinase 1 (PLK1) for the treatment of cancer and their use for the treatment of bacterial infections | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2015-12-24 | — | — | US | disclosed |
| US-20150368209-A1 | 4-Pyrimidinylamino-benzenesulfonamide derivatives and their use for the inhibition of polo-like kinase 1 (PLK1) for the treatment of cancer and their use for the treatment of bacterial infections | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2015-12-24 | — | — | US | disclosed |
| US-20150368209-A1 | 4-Pyrimidinylamino-benzenesulfonamide derivatives and their use for the inhibition of polo-like kinase 1 (PLK1) for the treatment of cancer and their use for the treatment of bacterial infections | ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL) (CH) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368209-A1 | 4-Pyrimidinylamino-benzenesulfonamide derivatives and their use for the inhibition of polo-like kinase 1 (PLK1) for the treatment of cancer and their use for the treatment of bacterial infections | PLK1, PLK2, PLK4 | CCNT1 523/4885CDK9 83/4885PLK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.